Chugai Seiyaku Kabushiki Kaisha

Masahide Aoki

Satoshi Tsuchiya

Masahiro Nishimoto

Atsushi Matsuo

Hirotaka Kashiwagi

Yoshikazu Nishimura

Satoshi Tanida

Nobuyuki Hori

Takahiro Kawai

Shoshin Yoshida

Takuma Kamon

Hiroko Ogawa

Kyoko Oguri

Tsutomu Sato

Hitoshi Yoshino

Yoshiyuki Furuta

Takuya Shiraishi

Kota Tanaka

Zengye Hou

Kentarou Seto

Aya Sakon

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides methods for producing peptide compounds. The inventors have found that a cyclic peptide compound can be produced efficiently by linking the N-terminal amino acid residue and the C-terminal amino acid residue of a peptide compound in a solvent containing one or more selected from the group consisting of water-immiscible solvents, water-soluble alkyl nitriles, and water-soluble ethers.

Methods for producing cyclic compounds comprising N-substituted amino acid residues

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Growing community of inventors

Shizuoka, Japan

Masahide Aoki